Ozempic vs Mounjaro Guide
Ozempic vs Mounjaro: the diabetes head-to-head, honestly read
−2.0+ %
A1c drop, tirzepatide arms (SURPASS-2)
~2×
weight loss vs semaglutide 1 mg
1 mg
the comparison-dose caveat
Ozempic (semaglutide) and Mounjaro (tirzepatide) are the two weekly injections that dominate type 2 diabetes care, and they met directly in SURPASS-2: over 40 weeks, every tirzepatide dose beat semaglutide on A1c reduction and roughly doubled its weight loss. The honest asterisk: the trial compared against semaglutide 1 mg, not today's 2 mg maximum, so the true gap at maximum doses is smaller than the headline. Tolerability was similar, GI-led on both. As always, coverage, price, and your own response decide more than trial averages do.
Highlights
Key takeaways
- 01
SURPASS-2 (40 weeks, type 2 diabetes): tirzepatide 5, 10, and 15 mg all reduced A1c more than semaglutide 1 mg, with weight loss roughly 8 to 12 kg vs 6 kg.
- 02
The comparison-dose caveat is real: semaglutide now goes to 2 mg for diabetes, which narrows (but does not erase) the gap seen against 1 mg.
- 03
Both improve glucose smartly: insulin release scales with blood sugar, so alone they rarely cause lows. Combined with insulin or sulfonylureas, both need a hypoglycemia plan.
- 04
Tolerability was comparable in the trial: the same GI list, escalation-focused, mostly mild to moderate.
- 05
Ozempic carries the longer record plus cardiovascular outcome evidence; Mounjaro carries the stronger metabolic averages. Your prescriber weighs those against your profile.
- 06
For weight specifically in diabetes, tirzepatide's advantage is consistent across trials, which is why insurance status often ends up the deciding vote.
Ozempic vs Mounjaro at a glance (type 2 diabetes)
| Dimension | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| A1c, SURPASS-2 (40 wks) | −1.86% at 1 mg | −2.0 to −2.3% by dose |
| Weight, SURPASS-2 | ~−6 kg at 1 mg | ~−8 to −12 kg by dose |
| Max diabetes dose | 2 mg weekly | 15 mg weekly |
| Common side effects | Nausea ~15–20%, GI-led | Nausea ~12–18%, GI-led |
| Outcome evidence | Cardiovascular benefit label (SELECT lineage) | Strongest metabolic averages; newer record |
SURPASS-2 compared against semaglutide 1 mg; the 2 mg dose arrived later and narrows the gap. Side-effect rates come from each program and are not perfectly cross-comparable. Educational figures, not predictions.
What did SURPASS-2 actually show?
Over 40 weeks in adults with type 2 diabetes on metformin, all three tirzepatide doses beat semaglutide 1 mg on A1c (reductions past 2 percentage points at the higher doses vs 1.86) and roughly doubled the weight loss (about 8 to 12 kg by dose vs 6 kg). More tirzepatide participants reached A1c below 5.7%, the normal range.
Those are meaningful, well-measured differences in the core diabetes outcomes, and they match the direction seen everywhere else these molecules are compared.
The comparison-dose caveat
SURPASS-2 ran against semaglutide 1 mg because that was Ozempic's maximum at the time. The 2 mg dose approved since then adds glucose and weight effect, narrowing the real-world gap at maximum doses. No head-to-head against 2 mg has settled the exact remainder.
Practical reading: tirzepatide likely retains an average advantage at the top of both ladders, smaller than the famous trial numbers suggest. Averages then meet your individual response, which no trial predicts.
Glucose control and hypoglycemia
Both drugs prompt insulin in proportion to blood sugar, which is why either alone rarely causes hypoglycemia. The picture changes with companions: insulin or sulfonylureas plus either medication can stack into genuine lows, and improving control usually means trimming those companions early. That is the medication succeeding, managed proactively.
Expect glucose to improve quickly on either, and log any lows (shakiness, sweating, sudden fog) next to dose days: those records drive the co-medication adjustments.
Is one easier to tolerate?
SURPASS-2 reported similar GI profiles: nausea, diarrhea, vomiting, constipation, concentrated during escalation, mostly mild to moderate, with comparable discontinuation rates. Neither is reliably the gentle one.
Individual variation dominates: some people genuinely fare better on one molecule, in both directions, and a logged rough titration on one is a legitimate reason to try the other.
Cautions shared by both
Identical class list: severe persistent abdominal pain (pancreatitis), right-sided pain after fatty meals (gallbladder), vomiting past 24 hours (dehydration and kidney strain), the thyroid C-cell exclusion for MTC or MEN2 history, and prompt attention for sudden vision changes, since fast glucose improvement can transiently worsen retinopathy.
Our dedicated Ozempic and Mounjaro side-effect guides carry each product's full numbers, timelines, and management playbooks.
Same-day clinician territory on either medication
- Severe stomach pain that persists, especially radiating to the back
- Vomiting lasting over 24 hours, or fluids not staying down
- Shakiness, sweating, or confusion, especially with insulin or a sulfonylurea
- Yellowing of the skin or eyes
- Sharp right-sided pain after fatty meals, or pain with fever
- Sudden changes in your vision
How to choose, and how switching works
Coverage and price first, as ever. Then history: cardiovascular risk profiles often favor semaglutide's outcome evidence; a primary push on weight and A1c often favors tirzepatide's averages. Then lived tolerability, judged on your own logged weeks at therapeutic doses.
Switching runs in both directions with established conventions, usually entering the new ladder at a low or middle step. Records make it factual: dose days, glucose surprises, side effects, and weight trend in DoseLog give the conversation its evidence.
FAQ
Frequently asked questions
Which is better, Ozempic or Mounjaro?
In SURPASS-2, tirzepatide beat semaglutide 1 mg on A1c and roughly doubled its weight loss, with similar tolerability. The caveat: semaglutide's 2 mg dose arrived later and narrows the gap. Coverage, history, and your own response typically decide.
Is Mounjaro's weight loss really double Ozempic's?
Against the 1 mg dose in the trial, roughly yes (8 to 12 kg vs 6 kg over 40 weeks). Against today's 2 mg maximum the difference is smaller, though tirzepatide's advantage is consistent across programs.
Do Ozempic and Mounjaro cause low blood sugar?
Alone, rarely: both scale insulin release to glucose. Combined with insulin or sulfonylureas, lows become possible on either, and improving control usually means trimming those companion doses early.
Can I switch between Ozempic and Mounjaro?
Yes, in both directions, as routine prescriber work with dose-entry conventions. Bring your logged glucose, side effects, and weight trend; they decide the switch better than averages do.
Track your GLP-1 journey on one quiet line.
Log your shot, injection site, meals, and side-effect severity together, and walk into your next appointment with a week-by-week picture instead of a guess.
Sources
- 1.Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). NEJM 2021. Find on PubMed ↗
- 2.Ozempic and Mounjaro prescribing information: dosing, adverse reactions, warnings. View label on DailyMed ↗
- 3.SELECT cardiovascular outcomes lineage for semaglutide; SURPASS program summaries for tirzepatide. Read on NEJM ↗
This guide is for general education and is not medical advice. It doesn't account for your personal medical history, other medications, or your individual situation, and it doesn't replace a conversation with your doctor or pharmacist. Do not start, stop, or change the dose of GLP-1 or any medication based on what you read here. If you think you have a medical emergency, call your local emergency number. DoseLog is a tracking app; drug and company names are used factually under nominative fair use, and DoseLog is not affiliated with, endorsed by, or sponsored by any manufacturer mentioned.
Keep reading
GLP-1 Comparison Matrix
Every GLP-1 medication compared: the full matrix
Wegovy vs Zepbound Guide
Wegovy vs Zepbound: the head-to-head, honestly read
Ozempic vs Wegovy Guide
Ozempic vs Wegovy: the same drug, two labels, one honest answer
Zepbound vs Mounjaro Guide
Zepbound vs Mounjaro: the same drug, two labels